Collaboration
propels innovation

Ichnos Glenmark Innovation

Who we are

Ichnos Glenmark Innovation, an alliance between Ichnos Sciences Inc. and Glenmark Pharmaceuticals Limited, combines internal prowess and external potentialities to create cutting-edge therapy solutions.

Solutions that treat hematological malignancies and solid tumors to bring new hope for patients, their families and healthcare professionals alike.

At a Glance

  • Diversity of immune cell engagement and indications across hematologic and solid tumors

  • Proprietary protein engineering platform allowing maximal flexibility and manufacturability of full length multispecific antibodies

  • Discovery engine to sustain innovation and drive long-term growth
  • A highly experienced management team with a combined experience of 144 years

  • Approximately 150+ employees singularly focused on pushing the boundaries of oncology cancer treatment/therapy

  • Scientific Advisory Board with extensive expertise in drug development, immuno-oncology, and protein engineering
Map

3 state-of-the-art centers of innovation in USA, Switzerland and India

  • Company headquarters in New York, USA, focused on clinical  development, general and administration

  • Biologics and early discovery research center at Biopôle, Lausanne in Switzerland

  • Small Molecule Research Center at Mahape in Mumbai, India

Robust pipeline

isb1442
isb2001_a
grc54276

Robust Pipeline

Latest Updates

CORPORATE UPDATE

30 April 2024